AR106200A1 - Moléculas de unión a antígeno biespecíficas de activación de células t - Google Patents
Moléculas de unión a antígeno biespecíficas de activación de células tInfo
- Publication number
- AR106200A1 AR106200A1 ARP160102985A ARP160102985A AR106200A1 AR 106200 A1 AR106200 A1 AR 106200A1 AR P160102985 A ARP160102985 A AR P160102985A AR P160102985 A ARP160102985 A AR P160102985A AR 106200 A1 AR106200 A1 AR 106200A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- seq
- lcdr
- hcdr
- variable region
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 13
- 102000036639 antigens Human genes 0.000 title abstract 13
- 108091007433 antigens Proteins 0.000 title abstract 13
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 title 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Una molécula de unión a antígeno biespecífica activadora de células T que comprende (a) una primera fracción de unión a antígeno que se une específicamente a un primer antígeno; (b) una segunda fracción de unión a antígeno que se une específicamente a un segundo antígeno; en la que el primer antígeno es un antígeno activador de células T y el segundo antígeno es CD33, o el primer antígeno es CD33 y el segundo antígeno es un antígeno activador de células T; y en la que la fracción de unión a antígeno que se une específicamente a CD33 comprende (i) una región variable de la cadena pesada, particularmente una región variable de la cadena pesada humanizada, que comprende la región determinante de la complementariedad de la cadena pesada (HCDR) 1 de SEQ ID Nº 14, la HCDR 2 de SEQ ID Nº 15 y la HCDR 3 de la SEQ ID Nº 16, y una región variable de la cadena ligera, particularmente una región variable de la cadena ligera humanizada, que comprende la región determinante de la complementariedad de la cadena ligera (LCDR) 1 de SEQ ID Nº 17, la LCDR 2 de SEQ ID Nº 18 y la LCDR 3 de SEQ ID Nº 19, o (ii) y una región variable de la cadena pesada que comprende la región determinante de la complementariedad de la cadena pesada (HCDR) 1 de SEQ ID Nº 22, la HCDR 2 de SEQ ID Nº 23 y la HCDR 3 de la SEQ ID Nº 24, y una región variable de la cadena ligera que comprende la región determinante de la complementariedad de la cadena ligera (LCDR) 1 SEQ ID Nº 25, la LCDR 2 de SEQ ID Nº 26 y la LCDR 3 de SEQ ID Nº 27.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188046 | 2015-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106200A1 true AR106200A1 (es) | 2017-12-20 |
Family
ID=54256613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102985A AR106200A1 (es) | 2015-10-02 | 2016-09-29 | Moléculas de unión a antígeno biespecíficas de activación de células t |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170114146A1 (es) |
| AR (1) | AR106200A1 (es) |
| TW (1) | TW201726736A (es) |
| WO (1) | WO2017055318A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| AR085403A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos |
| AR085404A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas de union a antigeno |
| US20130058936A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| NZ708182A (en) | 2013-02-26 | 2019-08-30 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
| EP3055329B1 (en) | 2013-10-11 | 2018-06-13 | F. Hoffmann-La Roche AG | Multispecific domain exchanged common variable light chain antibodies |
| ES2979976T3 (es) | 2014-08-04 | 2024-09-27 | Hoffmann La Roche | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
| WO2016079050A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| HUE051715T2 (hu) | 2014-11-20 | 2021-03-29 | Hoffmann La Roche | T-sejt-aktiváló bispecifikus antigénkötõ molekulák a FolR1 és CD3 ellen |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| AU2016329111A1 (en) | 2015-10-02 | 2018-02-08 | F. Hoffmann-La Roche Ag | Bispecific anti-CEAXCD3 T cell activating antigen binding molecules |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| WO2018200562A1 (en) * | 2017-04-24 | 2018-11-01 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibody agents |
| CN118772287A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| CN111742219A (zh) * | 2018-03-01 | 2020-10-02 | 豪夫迈·罗氏有限公司 | 用于新颖靶抗原结合模块的特异性测定法 |
| CA3115020A1 (en) * | 2018-12-21 | 2020-06-25 | Anne Freimoser-Grundschober | Antibodies binding to cd3 |
| WO2020142659A2 (en) * | 2019-01-04 | 2020-07-09 | Trio Pharmaceuticals, Inc. | Multi-specific protein molecules and uses thereof |
| CR20220637A (es) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19 |
| TW202243689A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥 |
| EP4469478A1 (en) * | 2022-01-26 | 2024-12-04 | Mabswitch Inc. | Bispecific molecule with tunable affinity to a targetted antigen |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CA2896359A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| MX2015010350A (es) * | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
| RU2694659C2 (ru) * | 2014-01-06 | 2019-07-16 | Ф. Хоффманн-Ля Рош Аг | Одновалентные модули-переносчики через гематоэнцефалический барьер |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2016
- 2016-09-28 WO PCT/EP2016/073046 patent/WO2017055318A1/en not_active Ceased
- 2016-09-29 AR ARP160102985A patent/AR106200A1/es unknown
- 2016-09-30 US US15/282,994 patent/US20170114146A1/en not_active Abandoned
- 2016-09-30 TW TW105131770A patent/TW201726736A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170114146A1 (en) | 2017-04-27 |
| WO2017055318A1 (en) | 2017-04-06 |
| TW201726736A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106200A1 (es) | Moléculas de unión a antígeno biespecíficas de activación de células t | |
| AR106199A1 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t | |
| AR106365A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| CR20170026A (es) | Anticuerpos anti-tau humanizados | |
| CO2017005388A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ECSP17012781A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| PE20221282A1 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
| EA201791754A1 (ru) | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20161431A1 (es) | Anticuerpos biespecificos que se unen a cd38 y cd3 | |
| AR106555A1 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
| EA201990331A1 (ru) | Мультиспецифические антигенсвязывающие белки и способы их применения | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX377716B (es) | Moduladores de aplnr y usos de estos. | |
| MX395074B (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| EA202191763A1 (ru) | Бифункциональная молекула анти-pd-1/sirp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |